报告题目：Advanced Monitoring of Biologicals and Anti-biological Antibodies in Inflammatory Bowel Disease
报 告 人：卞素敏（比利时鲁汶大学）
报告时间：2018年10月18日（星期四）上午10:00
报告地点：独墅湖校区二期云轩楼2301室
报告人简介：
Sumin held her PhD in Pharmaceutical Sciences from University of Leuven, Belgium since September 2018. Her doctoral research focused on therapeutic drug monitoring of biologicals used to treat patients with inflammatory bowel diseases and she was responsible for development of techniques to detect the biologicals and the immune response towards those biologicals. She is strongly passionate about rapid diagnostics and has expertise in immunoassays and point-of-care testing. She also has great interest in transitioning the lab-based technologies into high-value products that ultimately lead to personalized treatment for chronically ill patients.
报告摘要：
Inflammatory bowel diseases (IBD) are relapsing inflammation of the intestine characterized by flares and remission that typically involve young patients. Anti-TNF (eg. adalimumab), anti-integrin (vedolizumab) has been approved to treat IBD effectively. These biological contribute one of the heaviest medical expenditures in many countries. For example, up to 50% of patients on anti-TNF therapies are currently treated inappropriately. Overexposure results in economical misuse of drugs and a possibility of drug-related adverse events while underexposure leads to secondary loss of response and exposes the patients to disease progression. The production of anti-drug antibodies is one of the major contributors to the secondary loss of response. A rational approach to increase the biological efficiency would be to tailor the dosing individual through therapeutic drug monitoring (TDM) allowing in-time dose adaptation. TDM involves the measurements of both drug and anti-drug antibodies concentrations. TDM has found its role as a therapeutic tool in guiding adalimumab dosing in clinical practice, and as a potential tool in optimizing vedolizumab therapy. Accurate, precise and rapid detection of drug and antidrug antibodies concentrations are therefore crucial.